Исследование маркеров неспецифичного воспаления у больных гипертонической болезнью
Диссертация
У больных с исходно повышенными концентрациями С-реакгнвного белка выявлено достоверное его снижение на фоне 8 недельной монотерапии тпачндоподобным диуретиком (нндапамнд-ретард), которое коррелирует с гипотензивным эффектом. Снижение СРБ на лечении ингибитором АГ1Ф (периндопрнл) не зависит от достигнутого гипотензивного эффекта. У больных ГБ с повышенной экскрецией альбумина с мочой (МАУ… Читать ещё >
Содержание
- СПИСОК ИСПОЛЬЗУЕМЫХ СОКРАЩЕНИЙ
- ГЛАВА I. Обзор литературы
- Ы. Медиаторы «специфичного воспаления.».—.,.&bdquo
- 1. 2. С- реактивный белок и риск развития ГБ
- 1. 3. С- реактивный белок и суточный профиль АД
- 1. 4. С — реактивный белок и метаболический синдром. M
- 1. J". Неепецифичное воспаление И атеросклероз у Больных ГБ
- 1. 6. Неспецнфичное воспаление и поражение органов-мишеней
- 1. 7. Механизмы взаимосвязи между процессами неспеинфичного воспаления и ГБ
- 1. 8. Динамика С- реактивного белка при лечении антигипертензнвньшн препаратами
- 1. 9. Мочевая кислота сыворотки крови и неспецнфичное воспаление
- 1. 10. D-лактат и процессы воспаления у больных ГБ
- 1. 11. Перекнсное окисление лнпидов и неспецифичное воспаление у больных ГБ
- 2. 1. Материалы исследования
- 2. 2. Методы исследования
- 23. Условия обследования.,
- 2. 4. Статистн ческая обработка полученн ьгх данных
- 3. 1. Клиническая характеристика и показатели неспецифнчного воспаления у больных ГБ .,.,.,""
- 3. 2. Сопоставление СРБ, ИЛ-6 с клинической характеристикой, факторами риска сердечно-сосудистых заболеваний и показателями суточного профиля АД у больных
- 4. 1. Сопоставление концентрации СРБ, ИЛ-6, с гипертрофией и ремоделированием миокарда левого желудочка
- 4. 2. Сопоставление концентрации СРБ, ИЛ-6 со структурным состоянием брахиоцефальных артерий
- 4. 3. Сопоставление концентрации СРБ с вазомоторной функцией эндотелия
- 4. 4. Сопоставление концентрации СРБ, ИЛ-6 со структурнофункциональным поражением почек
- 6. 1. Динамика СРБ на фоне 8-недельной монотерапии периндоприлом
- 6. 2. Динамика СРБ на фоне 8-недельной монотерапии индапамидом ретард
- 6. 3. Динамика ИЛ-6, МДА, D-лактата у больных ГБ
Список литературы
- Арабидэе ГГ., Белоусов Ю. Б-, Варакнк ЮЛ." и др. Диагностика и лечение артериальной гипертонии (Методические рекомендации), Москва, 1997: С, 95
- Арабидэе Г. Г., Белоусов Ю, Б, Карпов Ю.А. Артериальная гипертония (Справочное руководство по диагностике и лечению). Москва, 1999- стр 139
- Барскова В.Г., Насонова В. А. Подагра и синдром ннсулннорезистентностн. Русский медицинский журнал 2003- том 11, Л? 23
- Владимиров Ю-А., Арчаков А. А. Перекненое окисление липидов в биологических мембранах. М.: Наука, 1972- стр 55−57
- Мясников. АЛ- Гипертоническая болезнь, Москва-Медгнэ 1954, стр 129
- Ощспкова Е. В, Мягкая артериальная гипертония и патология магистральных артерий головы. Диссертация на соискание ученой степени д. м, н, Москва 1995 г
- Титов ВН., Осипов В.Г, Атеросклероз, Роль эндогенного воспаления, белков острой фазы и жирных кислот. Москва: Фонд «Клиника XKI века „, 2003, стр 156−173
- S) Чазова И. Е“ Ощепкова Е. В., Чихладзс Н, М, Артериальная гипертония. Принципы диагностики и лечения (пособие для врачей). Москва 2005 г, стр 35
- Национальные рекомендации по профилактике диагностике н лечению артериальной гипертонии, ВНОК 2004 г, 2 пересмотр.
- Abramson JL, Vacearino V. Relation between physical activity and inflammation among apparently healthy middle-aged and order US adults. Archive Internal Medicine 2002- 162:1286−1292
- Alper AB Jr, Chen W, Yau L el all. Childhood uric acid predicts adult btood pressure: the Bogalusa Heart Study. Hypertension 2005- 45:34−38
- A mar J, Ruidavets JB, Peyrieux JC et ah C-reactfve protein elevation pulse pressure reduction in hypertensive subjects. Hypertension 2005- 46 (1): 151−155
- Araujo O.F., Pereira A.C., Maria do Rosario D et all. High sensitivity C-reactive concentration in a healthy Brazilian population. International Journal of Cardiology 2004−97:433−438
- Bautista LE, Vera LM, Arenas IA et all. Independent association between inflammatory markers (C-reactive protein, interleukin-6 and TNF-alpha) and essential hypertension. Journal of Human Hypertension 2005- 19(2): 149−154
- Blake GJ, Rifai N, Burning JE et al. Blood pressure, C-reactive protein, and the risk of future cardiovascular events. Circulation 2003- 108: 2993−2999
- Blake GJ, Ridker PM. Novel Clinical markers of vascular wall inflammation. Circulation research 2001- 89:763
- Blake GJ, Ridker PM, High sensitivity C-reactive protein for predicting cardiovascular disease: an inflammatory hypothesis. European heart journal 2001−22:349−352
- Block G, Dietrich M, Norkus EP et all, Factors associated with oxidative stress in hitman population. American Journal Epidemiology 2002- 156:274−285
- Bo S, Gentile L, Ciccone G et all. The metabolic syndrome and High C-reactive protein: prevalence and differences by sex in southern-European population -based cohort Diabetes Mctab Res Rev 2005- 21 (6):515−524.
- Braiser AR. Recinos A, Eledrisi MS, Vascular inflammation and the rennin-angiotensin system. Arteriosclerosis Thrombosis and vascular Biology, 2002,22:1257−1266
- Brantsma AH, Bakker SJ, de Zeeuw D et all. Urinary albumin excretion as a predictor of the development of hypertension in the general population. Journal American Society Nephrology 2006- 17(2): 331−335
- Bullo M, Carcia-Lorda. Megias I, Salal-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression-Obesity research 2003- 11:525−531
- Celermajer D. S, Testing endoyhclial function using ultrasound. J Cardiovasc Pharm 1998- 32(3): S29-S32
- Celermajer D. St Sorensen K.E., Gooch V.M. et all. Non-invaivc detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992- 340: 11 ll-l 115
- Chae CU, Lee RT, Rifai N et all. Blood pressure and inflammation in apparently healthy men. Hypertension 2001- 38:399−403
- Choi H, Dong Hee Cho, Hyan Ho Shin et all. Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension, Circulation 2004- 68:297−303
- Cifcova R, Frohlich J, Skodova Z et at. C-reactive protein and the risk of developing hypertension, A population study. Journal of Hypertension 2004- 22{ 2), s 262
- Clapp BR, Htrschfield GM, Stony C et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability, Circulation 2005- 111(12): 1530−1536
- Conen D, Martina B, Pcmichoud AP et al. Patients with never treated white coat hypertension do have increased concentrations of B-type natriuretic peptide and C-reactive protein, Journal of Hypertension 2005- 23 (2), s 199
- Cook DG, Mendall MA* Whincup Pi I et all. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000- 149(1): 139−150
- Coltone S, Vadala L, Cuarncry M et al. Relation of C-reactive protein to oxidative stress and to endothelial dysfunction in essential hypertension. Journal of hypertension 2005- 23(2), s 58.
- Cottone S, Vadala A, Riccobene R et all. Relationship of microalbuminuria, endothelin-l and growth factors in human essential hypertension. American Journal of Hypertension 1998- 11:11 A.
- Culleton BF, Larson MG, Kannel WB et all. Serum uric acid and risk for cardiovascular disease and death: the Framingham I leart study. Annals internal of medicine 1999- 13t: 7−13
- Das UN, Is obesity an inflammation condition? Nutrition 200t-17: 953−966.37. de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease- a review of risk prediction and interventions. Clinica Chemica Acta 2002- 317:1−15
- Deepak L, Bhatt, Eric J Topol. Need to test the arterial inflammation hypothesis. Circulation 2002- t06: 136−140
- Du Bois, Du Bois. Nomogram for estimation of adult body surface area from height and body mass. Arch Intent Med 1916- 17: 863
- Duk-Hee Kang, Sung-Kwang Park, In Kyu Lee, Johnson RJ, Uric acid induced C-reactive protein expression: implication on cell proliferation and nitric oxide production on human vascular cells. JASN 2005- 16: 35 533 562
- Duprez DA, Somasundaram PE, Sigurdsson G et al, Relationship between C-reactivc protein and arterial stiffness is an asymptomatic population. Journal of Human Hypertension 2005- 19(7): 515−519
- Engstrom G, Janzon L, Berglund G et all. Blood pressure increase and incidence of hypertension in relation to inflammation- sensitive plasma proteins. Arteriosclerosis, Thrombosis and Vascular Biology, 2002- 22: 20 542 058
- Ewachuk JB, Nay tor JM, Zello G A, D-lactate in human and ruminant metabolism. J Nutr 2005- 135:1619−1625
- Fliser D, Buchloz K, Hal 1er II. Antiinflammatory effects of angiotensin II subtype I receptor blockade in hypertensive patients with microinflammation. Circulation 2004- ПО: 1103−1107
- Florez H, Castilo-FIorez S, Mcndez A et all. C-reactivc protein is elevated in obese patients with the Metabolic syndrome. Diabetes Res Clin Pract 2006- 71(1):92−100
- Folsom AR. Peacock JMr Nieto FG et all. Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study, Journal of hypetension 1998- 16 (11): 1579−1583
- Ford E. S» Giles W, H" Mokdad Alih et all. Distribution and correlates of C-reactive protein concentrations among adults US women, Clinical Chemistry 2004- 50: 574−581
- Freitag MH. Larson MG, Levy D et all. Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart study. Hypertension 2003- 41:978−983
- Ganau A, Devereux RB. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension, JACC 1992- 19- 1550−1558
- Gerasymenko O, Kovalyova O. The dynamics of imerleukin-6 and C-reacuve protein levels in hypertensive patients treated by btsoprolol. Journal of Hypertension 2005- 23(2), s 164
- Ghiadoni L, Panichi V. Versari D el al, Markers of inflammation, endothelial function and blood pressure in untreated essential hypertensive patients, Journal of Hypertension 2003- 21{ 4), s 122
- Gibbons GH. Vascular risk factors for endothelial dysfunction. Clin Cardiol 1997−20 (11 suppl 2): 11−18−25
- GincT V, Totmos C, Chaves FJ et all, Microalbuminuria and oxidative stress in essential hypertension. Journal of internal medicine 2004- 255: 588−594
- Grundy SM. Obesity, metabolic syndrome and cardiovascular disease. The Journal of clinical endocrinology and metabolism 2004- 89 (6) — 2595−2600
- Grundy SM- Inflammation, Hypertension and the metabolic syndrome. JAMA 2003- 22: 3000−3002
- S) Hashimoto Ht Kitagawa K, Hougaku H, et ail. C-Reactive Protein Is an Independent Predictor of the Rate of Increase in Early Carotid Atherosclerosis Circulation. 2001- 104: 63−67
- Hassan MA, Hadi RA, Al-Rawi ZS et all. The glutathione defense system in the pathogenesis of rheumatoid arthritis. Journal of Applied Toxicology 2001 -21:69−73
- Hingorani AD, Cross J, Kharbanda et al. Aeute systemic inflammation impairs endothelium-depcndcnt dilatation in humans. Circulation 2000- 102:994−999
- Hunt SC, Stephenson SH, Hopkins PN el all. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 1991 — 17:969−976
- Jastrzebski M, C/ameeka D, Rajzer M et al. Heat shock protein 60 antibodies and chronic inflammation in essential hypertension. Journal of Hypertension 2003- 2I (4), s 240
- Jialal I, Dcvaraj S, Venugopal SK. C- reactive protein: risk marker or mediator in athcrothrombosis? Hypertension 2004- 44:6−11
- Johnson RJ, Rodriguez-lturbe B, Duk-Hee Kang et all. A unifying pathway for essential hypertension, American Journal of Hypertension 2005−18:431−440
- Johnson RJ, Feig DI, Herera-Acosta J et all. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005- 45:18−20
- Kamath S, Lip G. Fidrinogen: biochemistry', epidemiology arid determinants. QJ Med 2003−96:7t 1−729
- Kampus P. Kals J, Ristimae T et all, High sensitivity C-reactive protein affects ceniral hemodynamic and augmentation index in apparently healthy persons. Journal of Hypertension 2004- 22: 1133−1139
- Kaplan N. Clinical hypertension. (Fifth edition). Williams/Wtlkins 1990- P.466
- Kim Chul Sung. Jung Yul Suh, Bum Soo Kim el al. High Sensitivity C-reactive protein an independent risk factor for essential hypertension. American journal of hypertension 2003- 16:429−433
- Kiehl S, Werner P. Egger G et all. Active and passive smoking, chronic infections, and the risk of carotid atherosclerosis: prospective results from the BRUNECK STUDY. Stroke 2002- 33(9): 2170−2176
- Kim JS, Kang TS, Kim JB el all. Significant associations of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis 2006 Jun 16
- Kim JY, Chen J-C, Boyce PD et all, Occup. Exposure to welding fumes is associated with acute systemic inflammatory responses. Environ Med 2005−62:157−163
- Kofflcr S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sei (Lond) 2005- 10&(3):205−2I3
- Komats S, Panes J, Russel JM et al. Effect of chronic arterial hypertension on constitutive and induced intercellular adhesion molecule-1 expression in vivo. Hypertension 1997- 29: 683−689
- Kouisogiannis U, Karogiozakis V, Litsaas I. Association between C-reactivc protein, fibrinogen and microalbuminuria in essential hypertension. Journal of Hypertension 2003- 21 (4) — s 159
- Kul 1er LH, Tracy RP. The role of inflammation in cardiovascular disease. Arteriosclerosis, Thrombosis and Vascular Biology 2000- 20:901
- Larousse M, Bragulat E, Segarra M et a. t. Increased levels atherosclerosis markers in salt sensitive hypertension. American Journal of Hypertension 2006- l9(l):87−93-
- B3) Li H, Gong YC, Zhu DL. Essential hypertension is associated with subclinical inflammation. American Journal of hypertension 2004- 22(2): s 323
- Lue G- Bard J-M- Juhan-Vague I, et all. C-reactive protein, Interleukin-6, and fibrinogen as predictors of coronary heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003−23-I255
- Lyon CJT Law RE, Hsueh WA. Minireview: adiposity, inflammation and atherogenesis. Endocrinology 2003- 144(6):2195−2200
- Mahmud A, Feely J* Contribution of markers of vascular inflammation to arterial stiffness in essential hypertension, Journal of Human I lypertension 2005- 23 (2), s258
- Magyar MT, Szikszai Z, Balla J et all. Early-onset carotid atherosclerosis is associated with increased intima-media thikness and elevated serum levels of inflammatory markers. Stroke 2003- 34:58−63
- Makita S, Nakamura M, Hiramori K. The association of С-reactive protein levels with carotid tntima-media complex thickness and plaque formation in the general population. Stroke 2005- 36:2138−2142
- Marques-Vidal P, Cambou J-P, Bongard V et all. Systolic and diastolic hypertension: no relationship with lipid and inflammatory markers in Haute-Garonne, France, American Journal of Hypertension 2003- 16:681−684
- Mazzali M, Hughes J, Kim Yoon-Goo et all. Elevated uric acid increases bloods pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001- 38: 1101−1106
- McLelian AC, Phillips SA, Thomalley PJ Fluorimctric assay of D-Lacate. Ana! Biochem 1992- 206 (I):6−12
- Mendall MA, Patel P, Ballam L et all. С reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMG 1996- 312 (7038): 1061−1065
- Messerli AW, Seshadri N. Gregory L et al. Relation of albumin/creatinin ratio to C-reactive protein and to the metabolic syndrome. American Journal of Cardiology 2003- 92 (5):6I0−612
- Moncada S, Palmer RM, Higgs EA, el all. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991- 43- 109'142
- Muratori I, Corrado E, Di Chiara S et all. Relationship between endothelial dysfunction, intima media thickness hypertension and other cardiovascular risk factors in asymptomatic subjects. American Journal of hypertension 2005- 18:160A
- M iyashita Y, Saito I. Evaluation о f long-term Valsartan treatment on insulin resistance and high-sensitive C-reactive protein. The 21-scientific meeting of international society of hypertension, Fukuoka 2006. Abstract book, P02-I64
- Nakanishi N, Shiraishi T, Wada M. Association between fasting glucose and C-reactive protein m a Japanese population: the Minoh study. Diabetes Research Clinical Practice 2005- 6(1): 88−98
- Nakamura M, Onoda T, Fiai K el all. Association between serum C-reactive protein levels and microalbuminuria: a population based cross sectional studying northern Iwate, Japan. Internal medicinc 2004- 10: 919−925.
- Navai L, Heidari H, Kheirkhahi et all, Hypertension and its relation with serum urea, creatinine and uric acid in a pcriurban area in Tehran. Journal of Hypertension 2003- 21(4): s 266
- Neves MF, Amiri F, Virdis A et all. Role of aldosterone in angiotensin Il-induced cardiac and aortic inflammation, fibrosis, and hypertrophy Can J Physiol Pharmacol 2005- 83 (11): 999−3 006
- Nilson J. CRP-marker or marker of cardiovascular disease? Arteriosclerosis, Thrombosis and Vascular Biology 2005- 25:1527−1528
- Nisikimi T, Yoshinara F, Morimoto A, Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996,28:22−30
- Niskanen L, Laaksonen DE, Nyyssoncn K et ail. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004- 44 (6):859−865
- Niskanen LK+ Laaksonen DE, Nyyssoncn K et all- Uric acid as a risk factor for cardiovascular and all cause mortality in middle aged men: a prospective cohort study. Archive internal medicine 2004- 164: 1546−1551
- Ohta Y, Arita M, Furuta M et al. Association of high sensitivity C-reactive protein with essential hypertension. Journal of Hypertension 2005- 23 (2): s 323
- Papadogiannakis A, Xydakis D, Sfakianaki M et al. Low grade inflammation correlates with pulse and morning rise of blood pressure with hypertensive nephrosclerosis. Journal of Hypertension2005- 23 (2), s 329
- Pasceri V, Willerson JT, Edward TH el a. Direct proinflammatory effect of C-rcactive protein on human endothelial cells. Circulation 2000 102:2165−2168
- Pautieto P, Rattazzi M. Inflammation and hypertension- the search for link. Nephrol Dial Transplant 2006- 21: 850−853
- Pedrinelli R, Penno G, Pucci L et al- Inflammatory microalbuminuria, metabolic abnormalities and cardiovascular risk in non diabetic hypertensive men. Journal of Hypertension 2004- 22 (2), s 95
- Pedrrinclli R, DeirOmo G. Dt Bello V et a! Low grade inflammation and microalbuminuria in hypertension, Arteriosclerosis, Thrombosis and Vascular biology 2004- 24: 2414−2419
- Peetcrs AC, Netea MG, Janssen MC. Pro-inflammatory cytokines in patients with Essential hypertension. European Journal of Clinical investigators. 2001- 31(1) 31−36
- Pepys MB, Hirsch field GM. C-reactive protein: a critical update. The Journal of clinical investigation 2003- 11:1805−1812
- Perticone F, Maio R, Tripepi G et al. Inflammation mediates the link between endothelial dysfunction and mild to moderate renal insufficiency in essential hypertension. Journal of Hypertension 2005- 23 (2X $ 178
- PontremoHi R, Nieolclla R, Viazzi F et all. Microalbuminuria is an early marker of target organ damage in essential hypertension. American Journal of Hypertension, April 1998- 11:430−438
- Pupek-Musiallik D, Bogdanski P, Cymerys M et all. Does obesity aggravate inflammation in patients with hypertension? Journal of Hypertension 2003- 21(4), s29S
- Ridker PM, Danielson Er Rifai N et all. Valsarian, Blood pressure reduction and C-rcaclive protein. Hypertension 2006- 48:1−7
- Ridker PM, Cushman M, Stampher MJ et all. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine 1997- 336(14): 973−999.
- Ridker PM. Clinical application of C-rcaclivc protein for cardiovascular disease detection and prevention, Circulation 2003- 107:363 369
- Rifai N, Bumung JE, I-Min Lee et all. Is C-reactive protein specific for vascular disease in women? Annals of Internal Medicine 2002- 136: 529 533
- Ruggicro C, Cherubini A, Ble A et all. Uric acid and inflammatory markers. European Heart Joumal 2006- 27:1171 -1181
- Rutter MK, Meigs JB, Sullivan LM et alt. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study. Circulation 2004- 110:380−385
- Santos-Moreira Cr Alcantara PT Gato-Varela M et all. Haemorheologic altcrationsand carolid diickening in white coat hypertension. Journal of Hypertension 2006- 24 (4): s 287
- Schillaci G, Pirro M, Pasquatini L el all. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. Journal of hypertension 2003- 2t (10)-t84MS46
- Schi linger M, Exner Mr Mlckusch W et all. Inflammation and carotid artery- risk for atherosclerosis study (ICARAS). Circulation 2005−111:2203−2209
- Scsso HD, Buring JE, Blake GJ et all. C-reactive protein and the risk of developing hypertension. JAMA. 2003- 290:2945−2951
- Shiffrin E.L. Beyond blood pressure: the endothelium and atherosclerosis progression. American Journal of Hypertension 2002- (5:115s-122s
- Schmider RE, Veelken R, Schobcl H et all. Glomerular hyperiyltration dyring sympathetic nervous system activation in early essential hypertension. Journal American Society Nephrology 1997- 8:893−900
- Sinisalo J, Paronen J, Mat! lia KJ, Relation of inflammation to vascular function in patients with coronary heart disease, Atherosclerosis 2000- 149(2): 403−411
- Smith GD, Lawlor DA. Harbord A et all. Association of C-reactive protein with blood pressure and hypertension, Life course confounding and
- Mendeiian randomization (csts of causality. Arteriosclerosis, Thrombosis and Vascular Biology 2005- 25:1051−1056
- Stenvinkel P. C-reactive protein- docs il promote vascular disease? Nephrol Dial Transplant 2006- 21(10):2718−2720
- Slenvinkel P. Endothelial dysfunction and inflammation-is there a link? Nephrol Dial Transplant 2001- 16:1968−1971
- Stemlk L, Samee S, Shaff HV el al. C-reaciive protein retaxes human vessels in vitro. Arteriosclerosis, Thrombosis and Vascular Biology 2002−22:1865−1868
- Slrandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors and mortality in a prospective study in the elderly. Arteriosclerosis, Thrombosis and Vascular Biology 2000- 20:1057−1060
- Stuveling EM, Bakkcr Stcphan JL, HHlege HL ct at. C-reactive protein and microalbuminuria. Hypertension 2004- 43:791−796
- Stuveling E.M., Hillege H. L, Bakkcr Stcphan J, I et all. C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. Atherosclerosis 2004- 172:107−114
- Tatara Y, Onishi M, Ito N et al. Relationship between anerial stiffness and oxidative stress in patients with arterial hypertension. Journal of Hypertension 2005- 23(2) — s 332
- Tedgui A, Mallat Z- Antiinflammatory mechanisms in the vascular wall. Circulation research 2001- SB: 877−887
- Thompson C., Wilson W. In: Coronary risk factors and their assessment, Metanalysis of 37 000 patients' data obtained in US HGFP and UK MRC trials. Science Press, 1992
- Torzewski M, Rist C, Mortensen RF et all. C-reactive protein in the arterial intima. Role of C-reoctive protein receptor-dependent monocyte recruitment in atherogenesis Arteriosclerosis, Thrombosis and Vascular Biology 2000- 20:2094−2099
- Tsioufls C, Stougiannos P, Kakkavas A el al. Relation of ieft ventricular conccntric remodeling io levels of C-reactive protein and serum amyloid A in patients with essential hypertension, American Journal Cardiology 2005, 96(2)-2 52−256
- Tsioufis C, Dimitriadis K, Chatzis D et all. Relation of microalbuminuria to adiponectin and augmented C-reactivc protein levels in men with essential hypertension. American Journal of Cardiology 2005- 96: 946−951
- Tsioufis C, Dimitriadis, Taxiarchou D et all. Diverse associations of microalbuminuria with C-rcactivc protein, interleukin-18 and soluble CD 40 tigand in male essential hypertensive subjects. American Journal of Hypertension 2006- 19:462−466.
- Vaizquez-Otava G, Fernandez-Real JM, Zamora A et alt. Lowering of blood pressure leads to decreased circulating interleukin -6 in hypertensive subjects. Journal of Human Hypertension 2005- I9(6)-457~462
- Vallance P, Collier J, fihagat K. Infection, inflammation, and infarction- docs acute endothelial dysftmction provide a link? Lancet 1997- 349(9062): 1391−1392
- Vayssier-Tau5sat M, Camilli T, Aron Y et all. Effects of tobacco smoke and benzoo. p)Tcne on human endothelial cell and monocyte stress response. Am J Physiol Heart Cire Physiol 2001- 280:1293−1300
- Vaziri ND, Ding Y, Ni Z. Nitric oxide synthase expression in the course of lead-induced hypertension. Hypertension 1999- 34:558−562
- Venugopal SK, Devaraj S, Yuhanna I et all. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002- 106: 1439−144
- Verma S, Buchanan MR, Anderson IX Endothelial function testing as a biomarfccT of vascular disease. Circulation 2003- 10B.2054−2059
- Von Kane! R, Jain S, Mills PJ et alt. Relation of nocturnal blood pressure dipping to cellular adhesion, inflammation and haemostasis. Journal of Hypertension 2004- 22(11) — 2087−2093
- Vyssoulis GP, Martnakis AG, Karpanou EA et all. CRP: the unifying marker cardiovascular risk in arterial hypertension? American journal of Hypertension 2003- 15:246A
- Wang TJ, Byung-Ho Nam, Wilson PVF et all. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham heart study. Arteriosclerosis, Thrombosis and vascular Biology1 2002−22:1662−1667
- Wang CH, Li CH, Weisel RD et all. C-reactivc protein uprcgulates angiotensin type I receptors in vascular smooth muscle. Circulation 2003- 107:1783−1790
- Wang TJ, Byung-Ho Nam, Wilson PWF et all. Association of C-reactive protein with Carotid atherosclerosis in men and women: The Framingham Study. Arteriosclerosis, Thrombosis and Vascular Biology 2002- 22:1662−1667
- Wannamethee SG, Shapcr AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997- 78:147−153
- Watatnabe T, Yasunari K, Nakamura M cl ail. Carotid artery intima-media thickness and reactive oxygen species in hypertensive patients. Journal of Human Hypertansion 2006- 20- 336−340
- WiUerson J. T, Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 2004- 109(11) — II-2−1I-10
- Wolk R, Abu SM Shamsuzzaman, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension 2003- 42:1067−1074
- Won-Yong Lee, Jeong-Sik Park, Sang-Young Noh el al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. International Journal of Cardiology 2004- 97 (1): 101−106
- Yeun JY, Kaysen GA. C-reactivc protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD, Curr, Opinion. Nephrol. Hypertcns, 2000−9:621−630
- Zoccali C, Maio R. Mallamaci F et all. Uric acid and endothelial dysfunction in essential hypertension. Journal American Society of Nephrology 2006- 17: 1466−1471.